Please wait

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Name of Issuer)

(Title of Class of Securities)

(CUSIP Number)

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

X0202 SCHEDULE 13D/A 0000912282-26-000961 0001216017 XXXXXXXX LIVE 1 Common Stock, par value $0.0001 per share 08/19/2026 0001534133 38942Q202 CalciMedica, Inc. 505 Coast Boulevard South Suite 307 La Jolla CA 92037 Alafi Capital Company LLC (510) 663-7426 8 Admiral Drive, Suite 324 Emeryville CA 94608 Christopher D. Alafi (510) 663-7426 8 Admiral Drive, Suite 324 Emeryville CA 94608 Evan Ng (650) 565-2252 Dorsey & Whitney LLP 430 Cowper Street, Suite 250 Palo Alto CA 94301 0001216017 N Alafi Capital Company LLC OO CA 0 7220101 0 7220101 7220101 19.9 OO Includes 5,112,345 shares of common stock held directly by the Reporting Person, 130,651 warrants to purchase common stock at an exercise price of $7.15, 923,227 warrants to purchase common stock at an exercise price of $0.8033 and 923,227 warrants to purchase common stock at an exercise price of $1.00 held by the Reporting Person. Does not include 2,605,965 Series A Warrants or 2,605,965 Series B Warrants that are not currently exercisable due to the 19.99% beneficial ownership imitation included in such warrants. The calculation of percentage ownership is based on a total of 34,141,460 shares of Issuer common stock as of August 20, 2026, as set forth by the Issuer plus the total possible warrants that could be exercised by the Reporting Person. Y Christopher D. Alafi OO X1 7220101 0 7220101 0 7220101 19.9 IN Includes 5,112,345 shares of common stock held directly by the Reporting Person, 130,651 warrants to purchase common stock at an exercise price of $7.15, 923,227 warrants to purchase common stock at an exercise price of $0.8033 and 923,227 warrants to purchase common stock at an exercise price of $1.00 held by the Reporting Person. Does not include 2,605,965 Series A Warrants or 2,605,965 Series B Warrants that are not currently exercisable due to the 19.99% beneficial ownership imitation included in such warrants. The calculation of percentage ownership is based on a total of 34,141,460 shares of Issuer common stock as of August 20, 2026, as set forth by the Issuer plus the total possible warrants that could be exercised by the Reporting Person. Common Stock, par value $0.0001 per share CalciMedica, Inc. 505 Coast Boulevard South Suite 307 La Jolla CA 92037 The following constitutes Amendment No. 1 to the Schedule 13D filed by the undersigned ("Amendment No. 1"). This Amendment No. 1 amends the Schedule 13D as specifically set forth herein. This Amendment No. 1 was triggered solely to reflect the issuance of warrants to the Reporting Persons on August 19, 2026. None See Items 7-11 of the cover pages of this Statement and Item 2 above. Except to the extent of his or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record. This Amendment No. 1 is being filed to report that, on August 19, 2026, the Reporting Persons received 3,529,192 Series A Warrants and 3,529,192 Series B Warrants, following the receipt of Stockholder Approval. See Items 7-11 of the cover pages of this Statement and Item 2 above. Except to the extent of his or its pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record. This Amendment No. 1 is being filed to report that, on August 19, 2026, the Reporting Persons received 3,529,192 Series A Warrants and 3,529,192 Series B Warrants, following the receipt of Stockholder Approval. This Amendment No. 1 is being filed to report that, on August 19, 2026, the Reporting Persons received 3,529,192 Series A Warrants and 3,529,192 Series B Warrants, following the receipt of Stockholder Approval. Except as reported in this Statement, none of the Reporting Persons has effected any transactions in the Issuer's securities within the past 60 days. Not applicable. Not applicable. Alafi Capital Company LLC /s/ Christopher D. Alafi Christopher D. Alafi, as managing member of Alafi Capital Company, LLC 08/24/2026 Christopher D. Alafi /s/ Christopher D. Alafi Christopher D. Alafi 08/24/2026